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In recent years, the macrophage colony-stimulating
factor (M-CSF) and granulocyte-macrophage CSF
(GM-CSF) cytokines have been identified as
opposing regulators of the inflammatory program.
However, the two cytokines are simultaneously pre-
sent in the inflammatory milieu, and it is not clear
how cells integrate these signals. In order to under-
stand the regulatory networks associated with the
GM/M-CSF signaling axis, we analyzed DNA methyl-
ation in human monocytes. Our results indicate that
GM-CSF induces activation of the inflammatory pro-
gram and extensive DNA methylation changes, while
M-CSF-polarized cells are in a less differentiated
state. This inflammatory program is mediated via
JAK2 associated with the GM-CSF receptor and the
downstream extracellular signal-regulated (ERK)
signaling. However, PI3K signaling is associated
with a negative regulatory loop of the inflammatory
program and M-CSF autocrine signaling in GM-
CSF-polarized monocytes. Our findings describe
the regulatory networks associated with the GM/M-
CSF signaling axis and how they contribute to the
establishment of the inflammatory program associ-
ated with monocyte activation.860 Cell Reports 29, 860–872, October 22, 2019 ª 2019 The Authors
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Monocytes are short-lived blood mononuclear cells of myeloid
origin that are involved in inflammatory processes and innate im-
munity (Italiani and Boraschi, 2014; Wynn et al., 2013). In
response to inflammation, monocytes are rapidly recruited to
the injured tissue, where they are able to differentiate intomacro-
phage-like cells, guided by the cytokine milieu and the interplay
with other cells and microbial products. The combination and
magnitude of the environmental cues allow monocytes to adapt
to the different requirements during the inflammation process
(Lawrence and Natoli, 2011; Martinez and Gordon, 2014; Sica
and Mantovani, 2012). As a result, monocyte-derived macro-
phages can be found in different activation states, contributing
to the intensification of the inflammation or to its resolution by
producing anti-inflammatory cytokines and inducing tissue
repair (Biswas and Mantovani, 2010; Funes et al., 2018). To
develop the required level of plasticity, monocytes must be
able to respond to awide variety of pro-inflammatory and anti-in-
flammatory stimuli. Among these, granulocyte-macrophage col-
ony-stimulating factor (GM-CSF) and macrophage CSF (M-CSF)
have been found in recent years to be essential mediators during
monocyte polarization, since they can induce many of the
phenotypic features associated with pro-inflammatory and
anti-inflammatory states, respectively (Lacey et al., 2012; Sander
et al., 2017; Verreck et al., 2004).
The apparent antagonism between GM-CSF and M-CSF and
their central role during monocyte differentiation have led to.
creativecommons.org/licenses/by-nc-nd/4.0/).
both factors being proposed as valuable therapeutic targets. In
cancer, the polarization of tumor-associated macrophages
(TAMs) toward anti-inflammatory phenotypes has been linked
to tumor progression, suppression of T cell function, and angio-
genesis (Aras and Zaidi, 2017). GM-CSF and M-CSF signaling
fulfill opposing roles during infiltration and maturation of tumor
macrophages, and targeting the M-CSF receptor greatly re-
duces anti-inflammatory TAM infiltration in animal models and
cancer patients (Neubert et al., 2018; Ries et al., 2014; Van Over-
meire et al., 2016). On the other hand, GM-CSF targeting has
been explored in the context of treating autoimmune diseases,
giving rise to clinical trials for rheumatoid arthritis, psoriasis,
and asthma (Hamilton et al., 2016; Shiomi et al., 2016). Nonethe-
less, since the two cytokines can be simultaneously present in
the inflamed tissue, it is not clear how signaling is integrated dur-
ing monocyte cell fate decisions or whether monocytes can fully
reverse their phenotypes in response to apparently conflicting
polarization cues.
Epigenetic mechanisms that alter gene activity without
changes of the DNA sequence, such as DNA methylation or
post-translational modifications of histones, are critical during
cell differentiation. Recent studies have demonstrated that
monocytes undergo widespread epigenetic remodeling in
response to polarization signals including lipopolysaccharide
(LPS), b-glucan (BG), tumor necrosis factor (TNF), and GM-
CSF, suggesting that the chromatin acts as an integration
node during monocyte cell fate decisions in the inflammation
site (Park et al., 2017; Ramirez et al., 2017; Saeed et al., 2014).
To better understand how undifferentiated monocytes integrate
the GM-/M-CSF signaling axis at the chromatin level, we
analyzed DNAmethylation and assayed transposase-accessible
chromatin using sequencing (ATAC-seq) in ex vivo isolated
human monocytes. Our results indicate that integration of GM-
CSF and M-CSF signals differs significantly, showing opposing
actions that are reflected at the transcriptional and chromatin
levels.
RESULTS
Transcriptional Networks during Long-Term Monocyte
Polarization with M-CSF and GM-CSF
In order to study how transcriptional programs are modified dur-
ing polarization, we first differentiated human monocytes over
7 days with M-CSF (Mø-M monocytes) or GM-CSF (Mø-GM
monocytes). Transcriptome analysis of these cells with Hu-
manHT-12 v4 Expression BeadChips showed extensive reprog-
ramming in response to GM-CSF (2,501 differentially expressed
genes) and M-CSF (2,339 genes) (Figure 1A), although approxi-
mately 70% of the annotated genes were shared by Mø-GM
and Mø-M, indicating a close correlation between the two cell
populations (Figure 1B; Table S1). Gene ontology analysis indi-
cated that the regulated genes during monocyte polarization
perform functions typically associated with monocyte/macro-
phages, metabolism, and apoptosis (Table S2). We observed
that Mø-M preferentially overexpressed genes associated with
response to wounding (NINJ1, F13A1, SCARB1, and STAB1),
inflammation (AOAH, interleukin 10 [IL10], TLR7, A2M, etc.),
and endocytosis (FNBP1, CD209, SH3KBP1, and ITSN1), whilegenes overexpressed in Mø-GM were mostly those involved in
cell-cycle functions (CCNA2, CDC20, AURKA, PRC1, etc.), im-
mune response/inflammation (IL1B, CCL23, CXCL5, FCGR2B,
etc.), and glycolysis (ALDOA, LDHA, HK2, PFKP, GAPDH, etc.)
(Table S2). Many of these functions were also highlighted within
the topology of the functional interaction network derived from
the genes differentially expressed between Mø-GM and Mø-M,
including cell cycle, interferon response, adhesion/chemotaxis,
leukotriene synthesis, glucose metabolism, and intracellular
signaling (Figure 1C).
The fact that the proliferation signature was clearly overrepre-
sented inMø-GM raised a question about the proliferative poten-
tial of human monocytes (Figure S1A). In vitro polarization of hu-
man monocytes is often considered post-mitotic. However,
tracking cell division by CFSE staining confirmed that, while hu-
man monocytes are not highly proliferative in vitro, a small per-
centage of cells were able to complete one replication cycle after
7 days exposure to GM-CSF or M-CSF (Figure S1B), although
we observedmore proliferation inMø-GM cultures. This explains
the relative overexpression of cell-cycle-related genes in these
cells.
Correlation between Gene Expression and DNA
Methylation Changes in Polarized Monocytes
To investigate transcription regulation during polarization, we
studied this process at the epigenetic level, focusing our analysis
on DNA methylation. As a reference, we included undifferenti-
ated CD34+ cells in the DNA methylation analysis (Figure 2A).
Comparison of undifferentiated CD34+ with CD14+ monocytes
(Mo) confirmed that DNA demethylation was significantly more
frequent (9,660 demethylated regions, DM> 1.5 and an adjusted
false discovery rate [FDR] p < 0.05) than de novo methylation
(1,935) (Table S3), corroborating the demethylation trend associ-
ated with hematopoietic differentiation observed in other studies
(Lee et al., 2012; Kundaje et al., 2015; Rodriguez et al., 2015). On
the other hand, methylome analysis of human monocytes with
GM-CSF or M-CSF showed widespread DNA methylation
changes (Table S3). With this analysis we identified 2,051 differ-
entially methylated regions (DMRs) in Mø-GM (corresponding
to 1,051 genes) and only 740 (405 genes) in Mø-M (Figure 2A).
In addition, most DMRs in Mø-M were included in Mø-GM (Fig-
ure 2B), suggesting that Mø-M may represent a less differenti-
ated state. However, it should be pointed out that we annotated
219 DMRs that were specifically associated with M-CSF. In any
case, GM-CSF-induced polarization was associated with much
more extensive DNA methylation remodeling in which most (>
70%) of the DMRs corresponded to DNA demethylation events
(Figure 2C).
DNA methylation changes annotated during monocyte polari-
zation accumulated mostly in genes involved in immune func-
tions associated with monocytes/macrophages (Table S4),
although pro-inflammatory functions were more highly enriched
in Mø-GM. Gene ontology analysis showed that many of the
genes differentially methylated between Mø-GM and Mø-M
were associated with signal transduction (Table S4). These re-
sults were clearly observed in the functional interaction network
generated with these DMRs, in which signal transducers occu-
pied the most central position within the network (SRC, RHOG,Cell Reports 29, 860–872, October 22, 2019 861
Figure 1. Gene Expression Analysis in Mø-GM and Mø-M Cells
(A) Principal component analysis of gene expression profiles (three biological replicates, each of which was obtained from a pool of three individuals).
(B) Venn diagrams showing the number of genes differentially expressed during polarization with GM-CSF and M-CSF.
(C) Functional interaction networks of genes differentially expressed betweenMø-GM andMø-M cells. Mø-GM-upregulated genes are highlighted in blue; Mø-M
in red. Node size represents centrality (number of edges) in the network. Gene Ontology analysis includes only genes differentially expressed within the network.
Major functions are indicated within the network topology.and AKT) (Figure 2D). In addition, DNA methylation data were
validated by pyrosequencing analysis of seven genes annotated
as differentially methylated between Mø-GM and Mø-M in our
datasets (Figure 2E).
On the other hand, the distribution of all annotated DMRs ac-
cording to gene location showed that most changes accumu-
lated in the 50 UTR and gene body regions, but were less frequent
in the first exon and between the transcription start site (TSS) and
0.2 kb (TSS200) or 1.5 kb (TSS1500) upstream of the TSS of the
annotated genes (Figure 3A). Moreover, epigenetic marks often
act in a coordinated manner to fine-tune chromatin function
and transcription. To study how DNA methylation is associated
with histone marking in activated monocytes, we compared
our data with a previously published analysis of histone marking
in human monocytes activated with GM-CSF (3 days) (Schmidt862 Cell Reports 29, 860–872, October 22, 2019et al., 2016). In this study, H3K4me3 signals near TSS (±2.5 kb)
and H3K4me1 signals up- or downstream of the TSS (> 2.5 kb)
were used to define promoter and enhancer sites, respectively.
These regulatory regions were classified according to histone
occupancy in accessible promoters (H3K4me3+/H3K27Ac+),
poised promoters (H3K4me3+/H3K27me3+), strong enhancers
(H3K27Ac+/H3K4me1+), and poised enhancers (H3K4me1+/
H3K27me3+). We observed that approximately 20% of the an-
notated DMRs in response to GM-CSF or M-CSF were located
in accessible promoters and 12% in strong enhancers, while
they were mostly absent from poised regions (< 3%) (Figure 3B).
Finally, our data showed an inverse correlation between DNA
methylation and expression during polarization with GM-/M-
CSF in 231 genes associated with 266 CpG sites, most of which
(196 genes) were demethylated and overexpressed genes
Figure 2. DNA Methylation during Long-Term Polarization with M-CSF and GM-CSF
(A) Principal component analysis of DNA methylation profiles (two biological replicates, each of which was obtained from a pool of three individuals).
(B) Venn diagrams showing the number of DMRs acquired during polarization with GM-CSF and M-CSF.
(C) Volcano plots of regions differentially methylated during polarization. Demethylated probes are shown in blue and de novo methylated probes are in red
(DM > 1.5, p < 0.05).
(D) Functional interaction networks of genes differentially methylated between Mø-GM and Mø-M cells. Network centrality is indicated by the color scale and
node size.
(E) DNAmethylation analysis by bisulfite pyrosequencing of selected genes differentially methylated betweenMø-GMandMø-M cells. Demethylation is indicated
in green and de novo methylation is in red.(Figure 3C). These DMRs are frequently located in the 50 UTR and
gene body regions (Figure 3D), but histone occupancy data
showed that approximately 50% of the DMRs associated with
gene expression changes overlapped with chromatin regions
identified as accessible promoters (H3K4me3+/H3K27Ac+).This demonstrates that these DMRs are mostly located in regu-
latory regions associated with active transcription (Figure 3E).
Although M-CSF and GM-CSF are often considered to be
opposite polarization signals, our DNA methylation data sug-
gested that Mø-M cells are less differentiated than Mø-GMCell Reports 29, 860–872, October 22, 2019 863
Figure 3. Genomic Distribution of DMRs during Monocyte Polarization
(A) Distribution of DMRs by gene location. Results are represented as the ratio between observed and expected frequencies. Statistical significance was
evaluated by the hypergeometric test. *p < 0.01.
(B) DMR frequency in monocytes polarized with M-CSF or GM-CSF by histone occupancy in accessible promoters (H3K4me3+/H3K27Ac+), poised promoters
(H3K4me3+/H3K27me3+), strong enhancers (H3K27Ac+/H3K4me1+), and poised enhancers (H3K4me1+/H3K27me3+). The total number of DMRs is indicated
on each bar.
(C) Number of differentially expressed genes (> 2-fold change, p < 0.05) associated with DNAmethylation changes. Plus sign (+) indicates de novomethylation or
gene-expression upregulation; minus sign () indicates demethylation or gene-expression downregulation. Statistical significance was evaluated by the hy-
pergeometric test. *p < 0.01.
(D) Distribution of DMRs associated with gene expression changes according to gene location.
(E) Frequency of DMRs associated with gene expression changes according to histone occupancy in accessible promoters (H3K4me3+/H3K27Ac+), poised
promoters (H3K4me3+/H3K27me3+), strong enhancers (H3K27Ac+/H3K4me1+), and poised enhancers (H3K4me1+/H3K27me3+). The total number of DMRs is
indicated on each bar.cells, raising questions about the limits of plasticity between
differentially polarized monocytes, and whether the induced
epigenetic changes can be reversed. To study the DNA methyl-
ation dynamics associated with the GM-/M-CSF axis and to see
whether the methylation changes are reversible, we differenti-
ated monocytes with GM-CSF or M-CSF for 7 days and then
swapped the cytokines to redifferentiate for a further 7 days
(Figure 4).We used this method to analyze DNA methylation
levels in seven genes differentially methylated between Mø-
GM and Mø-M. Two of these (STAB1 and IL1RN) did not
respond to the cytokine switch and all the other analyzed genes
underwent demethylation after exposure to GM-CSF or M-CSF,
regardless of their previous polarization status. There was no
reversion of DNA methylation changes after the cytokine
switch, only the addition of new demethylation events. These
methylation changes were not due to the extended cultivation
period, since Mø-GM-specific genes did not respond to M-
CSF even after 14 days exposure to this cytokine (Figure S2).
Similarly, Mø-M-specific genes did not change their methyl-
ation status after a differentiation period of 14 days with GM-
CSF, indicating that the annotated changes were specifically864 Cell Reports 29, 860–872, October 22, 2019linked to the stimuli. Overall, these results suggest that the re-
sulting cells were not completely repolarized at the epigenetic
level after the cytokine switch, since they retained the DNA
methylation changes induced by each cytokine. However, we
also wanted to establish whether the exchange of the cytokines
was associated with functional changes or, conversely, if the
polarized cells were completely locked into a specific pheno-
type after their initial stimulation. First, we analyzed the phago-
cytic potential of these cells by measuring their ability to incor-
porate fluorescent-labeled zymosan. Although we observed
that Mø-M cells captured zymosan more efficiently (68.5%
labeled cells) than Mø-GM (42%), the phagocytic potential
decreased after the extended cultivation period (40%) and
non-significant differences were observed between groups
(Figure S3A). On the other hand, the cytokine profile (IL6,
IL19, CXCL1, CXCL5, and CXCL6) in cell supernatants showed
a moderate response to GM-CSF in Mø-M cells, implying that
they retain some plasticity (Figure S3B). We also tested two cy-
tokines associated with Mø-M polarization: IL10 and CCL2.
IL10 was undetected but we confirmed that CCL2 was pro-
duced in large quantities in response to M-CSF. However, the
Figure 4. DNA Methylation Analysis of Mø-GM and Mø-M Cells after In Vitro Cytokine Switching
Human monocytes were first polarized in vitro for 7 days (long-term polarization) with M-CSF or GM-CSF. After this period, cytokines were exchanged and cells
were allowed to differentiate for a further 7 days. DNA methylation levels were analyzed by pyrosequencing in three biological replicates. DNA methylation is
represented as the average percentage of methylation of all CpG sites within the amplified region. Differences between groups were assessed with a Student’s
independent-samples t test (two tailed) (± SD).addition of M-CSF did not significantly increase the production
of CCL2 in Mø-GM cells.
Transcriptional Reprogramming and Chromatin
Remodeling after Short-Term Polarization with GM-CSF
and M-CSF
Epigenetic and transcriptomic analysis of long-term polarized
monocytes could be the result of secondary signals associated
with the induction of other transcription regulators or even be
due to autocrine signaling throughout cytokine production. In
order to study how the GM-/M-CSF signal is integrated at the
chromatin level and reduce possible pleiotropic effects, we
analyzed chromatin accessibility (ATAC-seq) and mRNA tran-
scriptionafter only 12hexposure toM-CSForGM-CSF (hereafter
referred to as short-term polarization). By this method, RNA
sequencing (RNA-seq) profiles showed that GM-CSF exposure
induced a much more extensive transcriptional shift than
M-CSF (Figure 5A; Table S5). M-CSF-exposed cells showed a
phenotype intermediate between monocytes and GM-CSF-
exposed cells since 52% (533) of the M-CSF genes are also
inducedbyGM-CSF (Figure 5B). At theepigenetic level,weanno-tated3,219newly created regionsof accessible chromatin (ATAC
peaks) around the TSS, in contrast with M-CSF-treated mono-
cytes in which only 10 genes were annotated (Table S6). More-
over, among the 1,206 genes upregulated in response to GM-
CSF, 298 (24%) acquired at least one peak around the TSS,
including many inflammatory and immune-related genes such
as IL1B, CD1C, CXCL1, CXCL5, and CISH. In general, quantita-
tive analysis of the ATAC-seq signal across the whole length of
the gene indicated that genes overexpressed in response to
both cytokines showed overall greater chromatin accessibility
levels than the average values in other gene regions (Figure 5C).
In response to GM-CSF, overexpressed genes showed greater
chromatin accessibility (p = 0.005). This association was not
observed as clearly with M-CSF (p = 0.22) (Figure 5C).
We also wanted to evaluate how chromatin accessibility
was associated with histone occupancy. The increase of
ATAC-seq signaling in response to GM-CSF and M-CSF clearly
overlapped previously annotated regions in GM-CSF-activated
monocytes (Schmidt et al., 2016), including accessible pro-
moters (H3K4me3+/H3K27Ac+), poised promoters (H3K4me3+/
H3K27me3+), strong enhancers (H3K27Ac+/H3K4me1+), andCell Reports 29, 860–872, October 22, 2019 865
Figure 5. Transcriptional and Epigenetic Reprogramming during Short-Term Polarization
(A) Principal component analysis of RNA-seq data after 12 h exposure with M-CSF or GM-CSF in two biological replicates.
(B) Venn diagram showing the number of genes differentially expressed between untreated monocytes and monocytes exposed for 12 h with M-CSF and
GM-CSF.
(C) Quantitative analysis of normalized ATAC-seq signal in genes upregulated in response to GM-CSF or M-CSF. Whiskers represent 1.5 * interquartile range.
Differences between groups were assessed with a Mann–Whitney U test.
(D) Gene Ontology analysis of differentially expressed genes in response to both cytokines (12 h). Only the 10 top-ranked GO categories among upregulated and
downregulated genes are represented.
(E) Transcription and chromatin accessibility of representative genes. TSS is indicated by an arrow. RNA-seq and ATAC-seq signals are represented across the
entire length of the gene.poised enhancers (H3K4me1+/H3K27me3+) (Figure S4A). None-
theless, chromatin accessibility was greater in strong enhancers
when activated with GM-CSF than with M-CSF.
Gene ontology analysis showed that short-term polarization
induced upregulation of inflammatory and immune response
genes by GM-CSF, but induced downregulation after M-CSF
exposure (Figure 5D), arguing in favor of an opposing action.
As previously indicated, however, approximately 50% of M-
CSF-altered genes were also included in the GM-CSF program,
and included the upregulation of angiogenesis (WNT5A,
SERPINE1, ADM2, etc.) and cell adhesion pathways (LIMA1,
FERMT2, CTTN, CD93, SMAGP, etc.) and downregulation of866 Cell Reports 29, 860–872, October 22, 2019inflammation-related genes (LY75, LYZ, TNFRSF8, TLR5,
SERPINF1, CCR2, etc.) (Table S5). In any case, these transcrip-
tional dynamics were frequently associated with nucleosome
remodeling, including many genes associated with the inflam-
matory and immune response, such as IL1B, CXCL8, CXCL5,
ALOX5AP, and IL1RN, in which transcriptional overexpression
was associated with a gain of chromatin accessibility (Figure 5E).
Importantly, among the genes most overexpressed after GM-
CSF treatment were M-CSF, encoded by the CSF1 gene (552-
fold change), and the activin A, which is encoded by INHBA
(789-fold change), indicating that cytokine production occurs
very rapidly after activation.
Dissection of the GM-CSF-Mediated Signal
Transduction in Human Monocytes
Understanding how the signals in the tissue microenvironment
contribute to the activation of the inflammatory pathways inmac-
rophages is critical to the development of efficient immunomod-
ulatory therapies. The extensive transcriptomic and epigenetic
remodeling associated with GM-CSF exposure prompted us to
investigate in more detail how signal transduction mediated by
the GM-CSF receptor contributes to the development of the in-
flammatory program. Canonical GM-CSF receptor signaling is
dependent on the tyrosine kinase of jak 2 (JAK2), which triggers
the activation of the STAT5, Ras/mitogen-activated protein ki-
nase (MAPK) and PI-3 kinase (PI3K) pathways (Hercus et al.,
2009). However, it is not clear how each of these modules is
associated with inflammation or whether they act cooperatively
or by a self-regulatory mechanism. In order to study the specific
contribution of each signaling module, we pharmacologically in-
hibited GM-CSF receptor signaling mediated by JAK2 with rux-
olitinib (commonly used for treating myeloproliferative disorders)
and downstream at the MEK level with trametinib (used for mel-
anoma treatment), and inhibited PI3K with wortmannin (Fig-
ure 6A). The effective inhibition of each drug was validated by
western blot analysis of STAT5, AKT, and extracellular signal-
regulated kinase 1/2 (ERK1/2) phosphorylation (Figure 6A). Our
results indicated that, as expected, JAK2 inhibition with ruxoliti-
nib prevented signaling in all downstream signaling modules,
whereas trametinib only reduced ERK1/2 phosphorylation.
Nonetheless, it is important to note that although PI3K inhibition
produced total abrogation of AKT phosphorylation, it also
moderately reduced the level of ERK phosphorylation, suggest-
ing some crosstalk downstream of this pathway.
Analysis of chromatin accessibility showed that treatment with
any of the inhibitors resulted in the almost complete abrogation
of the GM-CSF-induced open chromatin regions around the
TSS (Table S6). Similarly, the increase of chromatin accessibility
associated with GM-CSF activation in regulatory regions identi-
fied by histone occupancy was also profoundly disrupted when
GM-CSF receptor signaling was blocked (Figure S4B), indicating
that the signaling pathways downstream of this receptor are crit-
ical for chromatin remodeling. In addition, we scanned the newly
created regions of accessible chromatin for transcription factor
(TF) binding motifs. We found that the M-CSF response was
associated with STAT binding motifs (STAT4, STAT5, and
STAT6) and the zinc finger protein ZNF168 (Table S7). Likewise,
the GM-CSF signature was much more clearly enriched with
STAT5 binding motifs (552 regions with the binding motif). This
result was expected because STAT5 is the canonical signaling
module downstream of the GM-CSF receptor. In general, the
GM-CSF response had a much richer TF binding profile that
included BATF, JunC, and Atf3 among its highest-ranked fac-
tors. Interestingly, the GM-CSF signature was almost totally
erased when GM-CSF signaling was inhibited, showing a TF
binding profile similar to the M-CSF-treated monocytes.
On the other hand, the differential contribution of each
signaling module was more clearly observed at the transcrip-
tional level, as shown by principal component analysis (Fig-
ure 6B; Table S5). This showed that treatment with GM-CSF in
the presence of the JAK2 inhibitor (iJAK) almost totally abro-gated the transcriptional changes associated with this cytokine,
whereas theMEK inhibitor (iMEK) had amuch weaker effect. The
latter result was expected, since only one signaling module was
affected. A more surprising finding was that treatment with the
inhibitor of PI3K (iPI3K) profoundly disrupted the GM-CSF
signaling program. To explore the functional contribution of
each signaling module, we performed gene clustering and
ontology analysis with all the induced genes in each sample
set with respect to untreated monocytes (Figure 6C). Clusters
C2, C3, C4, and C5 included genes upregulated in monocytes
after exposure to GM-CSF. These cluster profiles fade away in
the presence of iJAK, indicating that theyweremostly composed
of JAK2-dependent genes. Among them,most inflammatory and
immune response genes were identified in clusters C2 and C3,
including the inflammatory interleukins (IL1B, IL6, IL19, etc.)
and chemokines (CXCL5 and CXCL8). These two clusters were
also disrupted in the presence of iMEK but not by iPI3K, indi-
cating that the inflammatory program induced by JAK2 was in
part incorporated through the MAPK module. In some genes,
such as IL1B and CXCL5, these transcriptional changes were
accompanied by chromatin remodeling, and showed reduced
accessibility in response to iJAK and iMEK, but not with iPI3K
(Figure 6D). Clusters C4 and C5, on the other hand, corre-
sponded to JAK2-dependent genes whose expression was
mediated by the PI3K module and that included many genes
associated with intracellular signaling (PPARG, RTKN, NDRG2,
etc.), cytoskeleton (LIMK1 and ANK1), and immune function
(CCL24, IL36B, CD1A, etc.), although inflammatory genes were
mostly absent (Figure 6C). The CSF1 gene (encoding M-CSF)
was also included in cluster C5, indicating that M-CSF produc-
tion was mediated by the PI3K module (Figure 6D). In contrast,
the C6 cluster comprises a large subset of genes that were
only upregulated in cells treated with GM-CSF in the presence
of iPI3K. Interestingly, gene ontology analysis of this cluster
showed substantial enrichment of pro-inflammatory genes
(> 60 genes) (CCL20, CXCL1, CASP4, IL23A, etc.), while only
some, such as IL10, may be considered anti-inflammatory
genes, indicating that inhibition of the PI3K module stimulated
the inflammatory program. In addition, the cytokine profile in
the cell supernatant confirmed that iJAK and iMEK impaired
the release of many of the cytokines associated with the inflam-
matory response (IL6, IL19, CXCL1, CXCL6, and CXCL5) while
iPI3K produced the opposite effect, corroborating the pro-in-
flammatory role of the PI3K pathway in stimulated monocytes
(Figure S5A). Conversely, M-CSF had very different dynamics,
being the only cytokine that was more strongly inhibited by
iPI3K than by iMEK.
Finally, since M-CSF expression was also regulated by PI3K,
we examined whether the pro-inflammatory effect associated
with iPI3K could be mediated by the inhibition of M-CSF produc-
tion. With this aim, we blocked the M-CSF signal after GM-CSF
stimulation to see whether this enhanced the expression of in-
flammatory genes to a similar degree as PI3K inhibition. Neither
inhibiting M-CSF with a neutralizing antibody nor inhibiting the c-
fms tyrosine kinase activity of the M-CSF receptor produced a
significant increase in IL1B or IL6 expression levels, suggesting
that the overexpression of these genes was mediated by other
mechanisms (Figure S5B).Cell Reports 29, 860–872, October 22, 2019 867
Figure 6. Dissection of GM-CSF-Mediated Signaling Modules in Human Monocytes
(A) Simplified representation of the main signaling modules mediated by GM-CSF receptor and western blot analysis of GM-CSF signaling after 30 min of
stimulation in human monocytes. Activation of the PI3K signaling pathway was studied at the AKT level, and ERK1/2 phosphorylation was used to confirm in-
hibition of MEK activity. AKT (pan-AKT) and phospho-AKT (pAKT) correspond to the same samples probed in a different blot.
(B) Principal component analysis of RNA-seq profiles in GM-CSF-stimulated monocytes in the presence of iJAK, iMEK, or iPI3K (two biological replicates).
(C) Unsupervised gene cluster heatmap of induced genes (FC > 2) in Mo after stimulation with M-CSF and GM-CSF, or with the inhibitors of the JAK, MEK, and
PI3K pathways. Gene ontology analysis of each cluster is shown in the right panel.
(D) Transcription and chromatin accessibility of representative genes.
(E) Venn diagram showing the number of GM-CSF-upregulated genes that are dependent on the JAK2, MAPK, or PI3K pathways. The transcription factor binding
profile of each gene subset is shown in the right panel.Our pharmacological strategy enabled us to identify GM-CSF-
induced genes (upregulated or repressed, fold change [FC] > 2,
adjusted value of p < 0.05) that were JAK2 dependent and,
downstream, MAPK or PI3K dependent (a complete list of genes
is provided in Table S8). In this way, we identified 1,348 JAK2-
dependent and 1,368 JAK2-independent genes. In general, we
observed that the inflammatory program seemed to be preferen-
tially regulated through JAK2, although the JAK2-independent
gene subset was significantly enriched in chemokines (CXCL1,
CXCL2, CCL24, etc.) and some interleukins such as IL24 (Table
S8). Among the genes upregulated downstream of JAK2, there
were 462 MAPK-dependent and 357 PI3K-dependent genes,
most of which, as expected, were also JAK2 dependent (Fig-
ure 6E). On the other hand, enrichment analysis of conserved868 Cell Reports 29, 860–872, October 22, 2019TF binding sites among GM-CSF-upregulated genes had signif-
icantly different profiles. Upregulated JAK2-dependent genes
were considerably more enriched in TF binding sites, including
BACH1, STATs (especially STAT5A), and interferon-stimulated
response elements (ISREs). These were mostly absent from
the JAK2-independent gene subset. Conversely, MAPK-depen-
dent genes showed a similar TF profile to JAK2-dependent
genes, but nuclear factor kB (NF-kB) and AP1 were overrepre-
sented in this subset (although also present in the other gene
subsets), while PI3K-dependent genes were characterized by
an absence of STAT binding sites. Overall, these results indi-
cated that each signaling module is associated with a differential
TF signature, albeit one with common elements, including
BACH1, BACH2, and NF-kB.
DISCUSSION
Consistent with previous results (Lacey et al., 2012; Ushach and
Zlotnik, 2016), our data show that transcription profiles between
GM-CSF- and M-CSF-polarized monocytes give rise to
opposing phenotypes in the context of the inflammatory pro-
gram. However, it is not clear how monocytes integrate these
signals in vivo, since both cytokines are commonly found in the
inflammatory microenvironment (Hamilton, 2008). Our findings
indicate that epigenetic rewiring induced by GM-CSF is much
more extensive than by M-CSF, at least under our in vitro condi-
tions. It is possible that different culture conditions could pro-
duce different results and that a higher M-CSF concentration
might increase the degree of epigenetic remodeling during polar-
ization. Nonetheless, it is significant that most epigenetic
changes induced by M-CSF are also induced by GM-CSF, while
M-CSF was unable to induce most of the GM-CSF-stimulated
changes, especially those associated with inflammatory path-
ways. Thus, M-CSF-polarized monocytes emerged as being in
a less differentiated state, closer to undifferentiated monocytes
than to cells differentiated with GM-CSF. As a result, from a tran-
scriptional and epigenetic perspective, the notion that both cyto-
kines perform opposing actions is barely supported, at least with
respect to non-inflammatory functions. This is further reinforced
by the fact that none of the cytokines was able to reverse the
epigenetic changes induced by the others, and an additive effect
was all that was observed in the subset of genes analyzed after
cytokine switching. Although a genome-wide DNA methylation
analysis would have provided a more complete picture of the
plasticity associated with the epigenetic landscape acquired
during polarization, none of the analyzed genes showed rever-
sion of these changes. Therefore, it seems that polarized mono-
cytes maintain at least a partial epigenetic memory associated
with the different stimuli to which they have been exposed, while
retaining the potential to respond to new signals in the tissue
microenvironment, as demonstrated by the cytokine production
in Mø-M cells stimulated with GM-CSF. Interestingly, a previous
report described that M2-polarized monocytes retained the abil-
ity to respond to pro-inflammatory stimuli (LPS and interferon g
[IFNg]) while M1 cells were not capable of responding to IL4
(Van den Bossche et al., 2016). The authors demonstrated that
this process was due to a mitochondrial dysfunction in M1
monocytes that prevents the acquisition of M2 metabolic traits.
Therefore, these results suggest that the M1 phenotypes are
less phenotypically plastic, as they would represent a terminal
differentiation state, an interpretation that would be consistent
with the greater epigenetic drift that we observed in monocytes
polarized with GM-CSF.
The apparent duality between M-CSF and GM-CSF raises the
critical question about how the two cytokines are coupled at the
functional and molecular levels. To answer this, we investigated
the transcriptional and epigenetic rewiring during short-term po-
larization, reducing pleiotropic effects associated with the in vitro
differentiation process. Even within this experimental frame-
work, transcriptional profiles clearly show that M-CSF mono-
cytes have an intermediate phenotype closer to that of control
monocytes, while GM-CSF monocytes are associated, yet
again, with much more widespread transcriptional and epige-netic remodeling. Integration of the GM-CSF signal in the chro-
matin occurs rapidly and incorporates a significant fraction of
the inflammatory program that is absent fromM-CSF-stimulated
monocytes. Themechanisms bywhich GM-CSF induces deeper
epigenetic rewiring are not clear, although in vitro-differentiated
monocytes are known to differentially express epigenetic en-
zymes, including DNA methyltransferases (DNMTs), in response
to different stimuli (Kittan et al., 2013). Therefore, tight transcrip-
tional regulation of these enzymes may be essential for epige-
netic remodeling during polarization. Regardless of this, we did
not observe any differential expression of any DNMT enzyme be-
tween M-CSF and GM-CSF stimulation. Further studies are
needed to clarify this matter.
An important finding of our analysis is that GM-CSF stimula-
tion is intrinsically associated with the overexpression of M-
CSF, which is among the most highly upregulated genes
(> 500-fold change), as well as other cytokines that can poten-
tially initiate autocrine signaling, such as activin A (789-fold
change) and IL-19 (102-fold change). Indeed, transcriptional
overexpression of CSF1 (M-CSF) in response to GM-CSF has
been reported before in transcriptomic studies (Lacey et al.,
2012). Also, activin A production in response to GM-CSF has
been documented, demonstrating that its expression is associ-
ated with M1 skewing by blocking the acquisition of M2 pheno-
types (Sierra-Filardi et al., 2011). Consequently, stimulation with
GM-CSF is associated with a downstream autocrine signaling
cascade that fundamentally contributes to monocyte polariza-
tion. Regardless, M-CSF production in GM-CSF-exposed
monocytes explains the overlap of the transcriptional and epige-
netic programs induced by both cytokines.
The complex regulatory networks associated with GM-CSF
encouraged us to examine the GM-CSF signaling mediated by
its receptor in even greater detail, and we were able to demon-
strate that a very significant fraction of the inflammatory program
is directed through JAK2 and the downstream MAPK pathway.
Since MAPK targeting is enough to prevent a significant fraction
of the inflammatory program, it would be worth investigating
whether therapies that attempt to block GM-CSF, which is a
central mediator of inflammation and tissue destruction in auto-
immune diseases such as rheumatoid arthritis (RA) (Shiomi et al.,
2016), could be complemented by MAPK targeting. On the other
hand, blockage of the PI3K module stimulates the expression of
many genes associated with inflammation, suggesting that it
could act as a negative regulator of the inflammatory program
to prevent an exacerbated inflammatory response. This result
is consistent with a previous in vitro study in which the PI3K-
Akt pathway was associated with the negative regulation of
Toll-like receptor (TLR) signaling (Luyendyk et al., 2008). In vivo
studies have also revealed that inhibition of PI3K activity in septic
mice results in very significant increases in serum levels of in-
flammatory cytokines (IL1-b, IL-2, IL-6, IL-10, IL-12, and TNF-
a) (Williams et al., 2004). Specific PI3Kg inhibition has been
shown to convert TAMs into pro-inflammatory phenotypes
(Kaneda et al., 2016), suggesting that PI3K acts as a compensa-
tory mechanism that suppresses pro-inflammatory processes. It
should be noted that PI3K inhibition also strongly induces IL-10
expression, so the balance between pro- and anti-inflammatory
functions is not yet clear. In addition, it should bementioned that,Cell Reports 29, 860–872, October 22, 2019 869
in our study, we did not specifically dissect the STAT5 pathway.
Nonetheless, most JAK2-dependent genes that are not inhibited
by iMEK or iPI3K (which include important genes such as INHBA,
CISH, IL19, and CCL22) are probably STAT5 dependent, since
this is one of the major singling pathways associated with the
GM-CSF receptor.
It is important to highlight that, according to our data, CSF1
(M-CSF) overexpression in response to GM-CSF is regulated
by the PI3K pathway. Since our genomic data showed M-CSF
signaling to be associated with downregulation of the inflamma-
tory program, it was tempting to speculate that the negative
regulation of inflammation associated with the PI3K module
might be mediated by the induction of autocrine production of
M-CSF after GM-CSF stimulation. Nonetheless, our preliminary
data indicate that at least the overexpression of the pro-inflam-
matory cytokines IL-1b and IL-6 is not dependent on autocrine
signaling mediated by M-CSF, and that this mechanism might
be more complex. However, it is likely that the M-CSF may
help fine-tune the inflammatory program, since previous
in vitro competition experiments have shown that the balance
between the two cytokines can influence the polarization pro-
cess toward pro- or anti-inflammatory phenotypes (Broche´riou
et al., 2011). Relative levels of both cytokines have also proved
to be critical for the in vivo differentiation of macrophages during
infection withMycobacterium tuberculosis (Higgins et al., 2008),
and blockage of the M-CSF receptor was associated with a po-
larization shift toward M1 phenotypes in tumor-bearing mice
(Van Overmeire et al., 2016). In this context, both cytokines
compete at the cellular level and the autocrine production of
M-CSF via PI3K may contribute to the balance between them,
acting as a regulatory loop within the local microenvironment.
Overall, our study provides a comprehensive view of how hu-
manmonocytes integrateM-CSF andGM-CSF signaling in order
to generate stable gene expression patterns during polarization,
and how the two cytokines are functionally related during the
process. Since the GM/M-CSF axis is proving to be a promising
target in cancer and autoimmune diseases, understanding such
a relationship will be critical to the successful development of
suitable therapeutic strategies for treating these diseases.STAR+METHODS
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GAPDH (D16H11) XP Rabbit mAb Cell Signaling Technology Cat# 5174; RRID: AB_10622025
M-CSF (Clone 26730) R&D Systems Cat# MAB216-SP; RRID: AB_2085064
Biological Samples
Peripheral blood samples Asturias Transfusion Centre, Spain N/A
Chemicals, Peptides, and Recombinant Proteins
Recombinant human GM-CSF PeproTech Cat#300-03
Recombinant human M-CSF PeproTech Cat#300-25
Wortmannin Selleck Chemicals Cat#S2758
Trametinib (GSK1120212) Selleck Chemicals Cat#S2673
Ruxolitinib (INCB018424) Selleck Chemicals Cat#S1378
KI20227 Tocris Cat#4481/10
Cytochalasin D, actin polymerization inhibitor Abcam Cat#ab143484
Critical Commercial Assays
EZ DNA methylation kit Zymo Research Cat#D5001
PyroMark kit QIAGEN Cat#978703
RNAqueous-Micro kit Ambion Cat#AM1931
SuperScript II Reverse Transcriptase Kit Thermo Fisher Scientific Cat# 18064014
TruSeq Stranded mRNA Library Prep Illumina Inc. Cat#20020594
Phagocytosis Assay Kit (Green Zymosan) Abcam Cat#ab234053
HumanMethylation450KBeadChip Kit Illumina Inc. Cat#WG-314-1003
HumanHT-12 v4 Expression BeadChip Kit Illumina Inc. Cat#BD-103-0204
TargetAmp Nano-g Biotin-aRNA Labeling Kit Epicenter Cat#TAN07924
Nextera DNA Library Preparation Kit Illumina Inc. Cat#FC-121-1030
CFSE BioLegend Cat#423801
Premix Ex Taq master mix Takara Cat#RR003A
TB Green Premix Ex TaqII Takara Cat#RR820A
CD14 MicroBeads, human Miltenyi Biotech Cat#130-050-201
Agencourt AMPure XP beads Beckman Coulter Cat#A63881
Luminex Human Magnetic Assay (9-Plex) R&D Systems Cat#LXSAHM-09
Deposited Data
Raw microarray data This paper GEO: GSE123271
Raw RNA-seq and ATAC-seq data This paper GEO: GSE123574
Oligonucleotides
Primer for qPCR: human TPT1, sense primer:
50-GCAAGAACTGCAACAACAGC-30
This paper N/A
Primer for qPCR: human TPT1, reverse primer:
50-GCTGATGAGGGGAGACAGAG-30
This paper N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
Primer for qPCR: human CSF1, sense primer:
50-GATCGCGGACGGGTTGT-30
This paper N/A
Primer for qPCR: human CSF1, antisense primer:
50-TTCAGCGGAGGCATTTCC-30
This paper N/A
Primer for pyrosequencing, see Table S1 This paper N/A
Software and Algorithms
Bioconductor project Gentleman et al., 2004 https://www.bioconductor.org/
Lumi package Du et al., 2008 https://www.bioconductor.org/
Cytoscape Shannon et al., 2003 https://cytoscape.org/
Gephi Gephi - The Open Graph Viz Platform https://gephi.org/
FASTQC Babraham Bioinformatics https://www.bioinformatics.babraham.
ac.uk/projects/fastqc/
bowtie2 Langmead and Salzberg, 2012 http://bowtie-bio.sourceforge.net/
bowtie2/index.shtml
Picard Broad Institute http://broadinstitute.github.io/picard/
SAMtools view Li et al., 2009 http://www.htslib.org/doc/samtools.html
MACS2 Feng et al., 2012 https://github.com/taoliu/MACS
Diffbind Ross-Innes et al., 2012 https://www.bioconductor.org/
ChIPpeakAnno Zhu et al., 2010 https://www.bioconductor.org/
SeqMonk Babraham Bioinformatics https://www.bioinformatics.babraham.
ac.uk/projects/seqmonk/
STAR Dobin et al., 2013 https://github.com/alexdobin/STAR
RSEM Li and Dewey, 2011 https://github.com/deweylab/RSEM
GENCODE v26 Harrow et al., 2012 https://www.gencodegenes.org/
Homer (v4.10.4) Heinz et al., 2010 http://homer.ucsd.edu/homer/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Carlos
Lopez-Larrea (inmuno@hca.es). This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Blood Samples
Peripheral Blood samples were obtained from healthy adult donors from the Asturias Transfusion Centre, Spain, after obtaining their
written informed consent in accordance with the Declaration of Helsinki and the approved guidelines established by the Research
Ethics Board of the Spanish Research Council. Information about donors’ sex was not provided. Peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation. CD14+ monocytes were isolated from PBMCs by magnetic bead separa-
tion using human CD14 MicroBeads (MiltenyiBiotec). Isolated cells were >95% pure, as shown by flow cytometry analysis.
METHOD DETAILS
Isolation of Human Monocytes, Ex Vivo Differentiation, and Treatment
For long-term polarization, monocytes were cultured in RPMI medium (Life Technologies) supplemented with 10% FCS (Thermo
Fisher Scientific) and incubated with GM-CSF (1000 U/ml, PeproTech) or M-CSF (10 ng/ml, PeproTech) for 7 days. Cytokines
were added to the medium every 2 days. For short-term polarization (12 h), cells were incubated with M-CSF or GM-CSF in the pres-
ence wortmannin (250 nM), trametinib (75 nM) or ruxolitinib (600 nM) (Selleck Chemicals). M-CSF signaling was inhibited with the
c-fms tyrosine kinase inhibitor (KI20227, 100 nM) (Tocris) or with a neutralizing antibody against M-CSF (Clone 26730, 1 mg/ml)
(R&D Systems).e2 Cell Reports 29, 860–872.e1–e5, October 22, 2019
Western Blotting
Cells were prepared by SDS lysis extraction in the presence of PierceTM protease and phosphatase inhibitor (Thermo Fisher Scien-
tific). After SDS-PAGE, proteins were detected by western blot analysis with antibodies against STAT5, phospho-STAT5 (Tyr694),
ERK1/2, phosho-ERK1/2 (Thr202/Tyr204), phospho-AKT (Thr308), AKT (pan) and GAPDH (Cell Signaling Technology). Secondary
antibodies conjugated with HRP were obtained from Thermo Fisher Scientific.
Cell Division Analysis
Cell division was analyzed with carboxyfluorescein succinimidyl ester (CFSE) staining at 1.25 mM (20 min, room temperature)
(BioLegend). After incubation, CFSEwas blocked for 10minutes with 10%FCS (Thermo Fisher Scientific). Cell staining was analyzed
in a Gallios Flow Cytometer (Beckman Coulter).
Phagocytosis Assay
In vitro phagocytosis wasmeasured with FITC-labeled zymosan particles using a Phagocytosis Assay Kit (Green Zymosan) (Abcam).
Briefly, cells under each condition were incubated for 1 h with 20 mM cytochalasin D (Abcam) as a negative control. Then, cells were
incubated with FITC-zymosan particles for 3 h before analysis following the manufacturer’s instructions. In vitro phagocytosis was
quantified in a Gallios Flow Cytometer (Beckman Coulter).
Cytokine Detection and Measurement
Cell culture supernatants were collected and diluted 1:2 before analysis. Cytokine secretion was measured with a Luminex Human
Magnetic Assay (9-Plex) (R&D Systems) following the manufacturer’s protocol. This assay allowed the simultaneous detection of the
following cytokines: IL1B, IL6, IL10, M-CSF, CXCL5, IL19, CXCL6, CXCL1 and CCL2. After cytokine labeling, protein concentration
was measured in a Luminex 200TM system (Luminex Corporation).
Bisulfite Pyrosequencing
Sodium bisulfite modification of 500 ng of total DNA was performed with the EZ DNA methylation kit (Zymo Research) following the
manufacturer’s protocol. Modified DNA was amplified using the primers indicated in Table S9. After amplification, methylation levels
were quantified with a PyroMark kit (QIAGEN) and the PyroMark Q24 system (Biotage), following the manufacturer’s instructions.
Real-Time qRT-PCR
Total RNA was extracted using an RNAqueous-Micro kit (Ambion) and cDNA was synthesized from 1 mg of total RNA with a Super-
Script II Reverse Transcriptase Kit (Thermo Fisher Scientific). Quantification was performed with TaqMan Gene Expression Assays
(Applied Biosystems) for the IL1B (Hs01555410_m1) and IL6 (Hs00174131_m1) genes using Premix Ex Taq master mix (Takara).
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Hs02758991_g1) was used to normalize data, following the DDCt method.
Expression of CSF1 was analyzed with TB Green Premix Ex TaqII (Tli RNase H Plus) (Takara) and the tumor protein translationally
controlled 1 (TPT1) gene was used to normalize data. The 50-GCAAGAACTGCAACAACAGC-30 (sense) and 50-GCTGATGAGGGGA
GACAGAG-30 (antisense) primers were used to amplify CSF1; 50-GATCGCGGACGGGTTGT-30 (sense) and 50-TTCAGCGGAGG
CATTTCC-30 (antisense) were used to amplify TPT1.
DNA Extraction and Microarray Whole-Genome Methylation Profiling
Total DNA was extracted with a Genomic DNA Mini Kit (ATP Biotech), following the manufacturer’s recommended protocol. DNA
integrity was evaluated in TAE agarose gels. An EZ DNA methylation kit (Zymo Research) was used for sodium bisulfite conversion
of 500 ng of total DNA. Whole-genome DNA methylation was analyzed with an Infinium HumanMethylation450KBeadChip Kit (Illu-
mina Inc.), according to Illumina’s Infinium HD assay methylation protocol. Datasets were generated from two biological replicates
obtained from a pool of three individuals. Raw methylation data were decoded with GenomeStudio software (Illumina Inc.).
RNA Extraction and Microarray Whole-Genome Gene Expression Characterization
Total RNA was extracted using an RNAqueous-Micro kit (Ambion). RNA size and integrity were analyzed in RNA Nano Chips with a
Bioanalyzer 2100 (Agilent), and genome expression was characterized with a HumanHT-12 v4 Expression BeadChip Kit (Illumina
Inc.). Datasets were generated from three biological replicates obtained from a pool of three individuals. cRNA was synthesized
with a TargetAmp Nano-g Biotin-aRNA Labeling Kit for the Illumina System (Epicenter). Amplification, labeling and hybridization
were then performed according to Illumina’s Whole-Genome Gene Expression Direct Hybridization Protocol. Raw expression
data were obtained with GenomeStudio analytical software (Illumina Inc.).
Microarray Analysis
Raw data from GenomeStudio were analyzed using R packages from the Bioconductor project (Gentleman et al., 2004). Methylation
data were background-corrected, log2-transformed, quantile-adjusted for color balance, and quantile-normalized with the lumiCell Reports 29, 860–872.e1–e5, October 22, 2019 e3
package (Du et al., 2008). Gene expression data were background-corrected and log2-transformed. Probes with detection values of
p > 0.01 were removed. To analyze DNA methylation, sex chromosomes were eliminated and site locations were recorded using Il-
lumina’s HumanMethylation450k annotations. Between-group pairwise methylation and expression comparisons were quantified. A
linear model was fitted to the data and empirical Bayes-moderated t-statistics were calculated with the limma package. False dis-
covery rates (FDRs) were adjusted using the Benjamini–Hochberg procedure. For gene expression data, only probes with an
adjusted FDR p < 0.05 and >2-fold absolute value were analyzed. For DNA methylation we selected probes with an M-difference
(DM) >1.5 and an adjusted FDR p < 0.05. Functional interaction network data were obtained from STRING v10 (Szklarczyk et al.,
2015) and then built using Cytoscape software (Shannon et al., 2003). The resulting network was exported to Gephi, whereupon
graphs were derived using the Fruchterman–Reingold clustering algorithm (https://gephi.org/). Gene ontology (GO) enrichment anal-
ysis was performed with the DAVID Web-based tool (https://david.ncifcrf.gov/).
Fast-ATAC and Sequencing
To analyze chromatin accessibility, we followed the Fast-ATAC protocol, which is specifically adapted for blood cells (Corces et al.,
2016). Two biological replicates were used per condition. Briefly, 5,000 cells were resuspended in 50 mL of tagmentation mixture
(25 mL TD buffer, 2.5 mL TDE1, 0.5 mL 1%digitonin and 22 mLwater) (Nextera DNA Library Preparation Kit, Illumina Inc.) and incubated
at 37C for 30minutes. After tagmentation, DNAwas purifiedwithMinElute PCRPurification kit and amplified as previously described
(Buenrostro et al., 2013). A double-size selection using Agencourt AMPure XP beads was performed based on the ATAC-seq Pro-
tocol from Kaestner Lab (https://www.med.upenn.edu/kaestnerlab/protocols.html). Sequencing was carried out using a HiSeq 4000
platform (Illumina Inc.). Raw read data were converted into FASTQ format, and quality control was assessed using the FASTQC soft-
ware (Babraham Bioinformatics). Adapters used for sequencing were removed with TrinGalore (Babraham Bioinformatics). Reads
were aligned with bowtie2 (Langmead and Salzberg, 2012), mapping against the Human Genome 38 reference (hg38). The alignment
was performed with the command ‘‘bowtie2 -X 2000–n 2,’’ which supports paired-end read sequencing. Reads mapped to mito-
chondrial and unknown, random or sex chromosomes were removed. Duplicated reads were removed with Picard (http://
broadinstitute.github.io/picard/) MarkDuplicates. Low-quality reads (MAPQ < 10) were removed using SAMtools view (Li et al.,
2009). Results of the read mapping were exported as input for peak calling. In this step, peaks were called by MACS2 software
(Feng et al., 2012) using the corresponding control group to call the peaks of the experimental group. MACS2 was run twice,
once for single nucleosome detection with the following parameters (-g ‘‘hs’’ -p 0.01–nomodel–shift 37–extsize 73 –broad) and
a second time for extended nucleosome detection (-g ‘‘hs’’ -p 0.01–nomodel–shift 100–extsize 200 –broad). Peaks of different
experimental groups were compared using the Diffbind package (Ross-Innes et al., 2012), which yielded a set of differentially called
peaks for each comparison. Those peaks were annotated and functionally characterized using the ChIPpeakAnno package (Zhu
et al., 2010). To quantify the ATAC-seq signal along the entire length of the gene, we used a sliding window of 1,000 nucleotides
to count the number of reads in each region. For each gene (hg38 genome), we took the region between the beginning and end
of the gene and assigned an FPKM value to each gene. The FPKM values were calculated as (number of reads) / (1,000 3 number
of windows with signal in the gene3 length window). We corrected sample bias with the Bland-Altman normalization by pairs, using
the undifferentiated monocyte as the reference. This step was performed independently for each replicate. For visualization, ATAC
signals were distributed in 200-bp windows, read counts where corrected to reads per million, and normalized according an aver-
aged distribution of quantitated values across all datasets using SeqMonk tools (Babraham Bioinformatics). Motif enrichment was
analyzed using HOMER (v4.10.4) (http://homer.ucsd.edu/homer/) (Heinz et al., 2010). Specifically, the ‘‘findMotifsGenome.pl’’
wrapper script was called to enable the use of the HOMER algorithm to evaluate the enrichment of known motifs. The input of
this step is a list of genomic coordinates corresponding to the open chromatin regions detected by the ATAC seq experiment for
each of the groups analyzed.
RNA Sequencing and Gene Expression Analysis
RNA was extracted from the same samples used for FAST-ATAC with an RNAqueous-Micro kit (Ambion). Integrity was analyzed in
RNA Nano Chips with a Bioanalyzer (Agilent). Starting from 400 ng of total RNA, sequencing libraries were prepared following the
‘‘TruSeq Stranded mRNA Sample Preparation Guide (Part # 15031047 Rev. E),’’ with the corresponding kit (Illumina Inc. Cat.#
RS-122-2101 and RS-122-2102, Set A and Set B, respectively). Sequencing was carried out using a HiSeq 2500 platform (Illumina
Inc.). After trimming for adapters using trim_galore (Babraham Bioinformatics), reads were mapped using the STAR program (Dobin
et al., 2013) against human genome (hg38), and the genes and transcripts were quantified with the RSEM program (Li and Dewey,
2011) using GENCODE v26 (Harrow et al., 2012). We used the TMMmethod and limma-voom transformation from rounded expected
counts to normalize the non-biological variability (Ritchie et al., 2015). Differential expression between groups was evaluated using
moderated t-statistics. Transcription factor enrichment of differentially expressed genes was analyzed by DAVID Web-based tool
(UCSC_TFBS algorithm).e4 Cell Reports 29, 860–872.e1–e5, October 22, 2019
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses were performed by Student’s t test andMann-Whitney U test using SPSS 16.0 software (IBM SPSS, Chicago, IL).
The number of replicates are indicated in the legend of each figure. All data shown are the mean (±SD) of at least two biological rep-
licates. Values of p < 0.05 were considered significant.
DATA AND CODE AVAILABILITY
Rawmicroarray data have been deposited in the NCBI Gene Expression Omnibus under accession number GEO: GSE123271. RNA-
seq and ATAC-seq raw data were submitted to the NCBI Gene Expression Omnibus under accession number GEO: GSE123574.Cell Reports 29, 860–872.e1–e5, October 22, 2019 e5
